BusinessCURE Pharmaceutical Secures Two Patents for the Extraction and Purification of Bioactive Cannabinoid MoleculesBy Nasdaq OMXApr 4, 2018, 12:57 PM UTC
BusinessCURE Pharmaceutical Reports Strong Progress and Sets Growth Roadmap for Remainder of YearBy Nasdaq OMXApr 3, 2018, 12:57 PM UTC
BusinessCURE Pharmaceutical Adds Healthcare Luminary To Advisory Board, Secures $1 Million Investment as a Bridge to UplistingBy Nasdaq OMXFeb 21, 2018, 11:00 AM UTC
BusinessCure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product For Sleep DisordersBy Nasdaq OMXNov 7, 2017, 2:00 PM UTC
BusinessCURE Pharmaceutical Announces Entrance Into Booming Pharmaceutical Cannabis IndustryBy Nasdaq OMXMay 10, 2017, 1:01 PM UTC
BusinessCURE Pharmaceutical Announces Entrance Into Booming Pharmaceutical Cannabis IndustryBy Nasdaq OMXMay 10, 2017, 1:01 PM UTC
BusinessCURE Pharmaceutical Strengthens Senior Leadership Team with Appointment of Industry Veteran Richard Serbin as Head of Global Corporate DevelopmentBy Nasdaq OMXMay 9, 2017, 1:02 PM UTC
BusinessCURE Pharmaceutical Strengthens Senior Leadership Team with Appointment of Industry Veteran Richard Serbin as Head of Global Corporate DevelopmentBy Nasdaq OMXMay 9, 2017, 1:02 PM UTC
